Literature DB >> 24671319

An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis?

Mark D Russell1, Deepak Singh-Ranger, James Crosbie.   

Abstract

Highly active antiretroviral therapy (HAART) has dramatically improved the morbidity and mortality of patients with HIV. Although the incidence of AIDS-defining neoplasms is decreasing with this therapy, they must still be considered in patients who present with suspicious symptoms. Early diagnosis and treatment may help to improve quality of life and clinical outcome. We report the case of a 30-year-old man on HAART who presented with an expanding lump in the left groin, thought to be a haematoma for 5 months. A high level of suspicion led to a prompt diagnosis of Burkitt's lymphoma followed by timely treatment with chemotherapy. This culminated in complete remission, with an improved quality of life.

Entities:  

Mesh:

Year:  2014        PMID: 24671319      PMCID: PMC3975495          DOI: 10.1136/bcr-2013-202669

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign.

Authors:  D P Steensma; T E Witzig
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

2.  Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

Authors:  L Ratner; J Lee; S Tang; D Redden; F Hamzeh; B Herndier; D Scadden; L Kaplan; R Ambinder; A Levine; W Harrington; L Grochow; C Flexner; B Tan; D Straus
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Potential antiretroviral drug interactions with cyclophosphamide, Doxorubicin, and Etoposide.

Authors:  Mark Bower; Tom Powles; Justin Stebbing; Christina Thirlwell
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 4.  AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

Authors:  Matthew C Cheung; Liron Pantanowitz; Bruce J Dezube
Journal:  Oncologist       Date:  2005 Jun-Jul

5.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

6.  Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.

Authors:  E Martínez; A Milinkovic; E Buira; E de Lazzari; A León; M Larrousse; M Loncá; M Laguno; J L Blanco; J Mallolas; F García; J M Miró; J M Gatell
Journal:  HIV Med       Date:  2007-05       Impact factor: 3.180

7.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

Review 8.  HIV infection and lymphoma.

Authors:  K L Grogg; R F Miller; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

9.  Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.

Authors:  Harutaka Katano; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-23       Impact factor: 11.205

Review 10.  HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.

Authors:  J I Cohen
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.